NMPA-2021-0084-V084

Type IB variation for application NMPA-2021-0084. Type IB variation: Formulation Change for Semaglutidex — critical change

Variation Number
NMPA-2021-0084-V084
Type
Type IB
Application
NMPA-2021-0084
Change
CHG-2021-0084
Status
Failed
Fee
€2,378
Submitted
2023-04-24
Approved
—
Description

Type IB variation: Formulation Change for Semaglutidex — critical change